Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)

Sponsor
University Health Network, Toronto
Study ID
NCT07524114
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This study will collect, annotate, and sequence biospecimens (blood, tissue, urine, saliva and surgery drainage) from patients across different cancer types to detect molecular residual disease (MRD). Imaging scans and clinical data will also be gathered. This will allow for early cancer interception, and hopefully prolong relapse-free survival across tumor types. Results of ctDNA testing will be provided for clinical decisions and to determine eligibility for other linked interventional interception therapeutic studies, each of which will have a separate protocol.

Key Dates

First listed
Apr 13, 2026
Start date
Mar 31, 2026
Status verified
May 2026
Primary completion
Mar 31, 2031
Completion
Mar 31, 2031

Study Design

Enrollment
7,000 participants (estimated)

Primary Outcome Measure

To collect, annotate, and analyze biospecimens for the detection of MRD [ Time Frame: 5 years ]

Central Contacts

Find similar trials

Nationwide
Breast cancer trialsHead and neck cancer trialsLung cancer trialsMelanoma trialsOncology trialsBreast oncology trialsWomen's health trialsENT trialsLung oncology trialsLung disease trialsSkin cancer trialsDermatology trials

Related Studies